Compare BridgeBio Pharma Inc (BBIO) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Hasbro, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Hasbro, Inc. trades at $97.28 (market cap $13.33B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Hasbro, Inc. pays a 2.96% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | HAS | |
|---|---|---|
Market Cap | $16.61B | $13.33B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $105.88 |
52-Week Low | $47.29 | $70.95 |
Enterprise Value | $18.16B | $15.52B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Hasbro (HAS) trades at $93.52, up 2.0% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth driven by Magic: The Gathering and digital gaming, though net income turned negative in 2025. Analyst consensus is a Buy with a $104.90 price target, supported by institutional accumulation and positive media coverage on franchise strength.
Outlook remains positive with 2026 revenue projected at $5.0B and net income of $794M, but risks include high debt levels, margin pressures from tariffs, and cybersecurity concerns. The stock offers a 2.93% dividend yield, with upside potential if growth sustains, yet volatility may persist amid cost headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
